表皮生长因子受体（EGFR）抑制剂治疗期间的皮肤不良反应。
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
作者信息
Santoro Francesca, Cozzani Emanuele, Parodi Aurora
机构信息
Di.S.E.M. Section of Dermatology, University of Genoa, Italy.
出版信息
J Dermatolog Treat. 2006;17(3):160-1. doi: 10.1080/09546630600688523.
The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of solid tumours is now increasing. Cutaneous side effects, namely acneiform eruption, xerosis, telangiectasia, hyperpigmentation, fissures, hair and nail changes, are reported in literature. We describe a case of a man treated with an EGFR-inhibitor (erlotinib) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution.
表皮生长因子受体（EGFR）抑制剂在实体瘤治疗中的应用目前正在增加。文献报道了其皮肤副作用，即痤疮样皮疹、皮肤干燥、毛细血管扩张、色素沉着、皮肤皲裂、毛发和指甲改变。我们描述了一例接受EGFR抑制剂（厄洛替尼）治疗的男性非小细胞肺癌患者，其皮肤表现出现在一个不常见的部位且演变过程不典型。
Zotero 插件